SHANGHAI, July 13 (Reuters) – The value of China’s innovative drug out-licensing deals reached about $110 billion between January and June, a record high, state broadcaster CCTV reported Monday, citing data from the National Medical Products Administration. • As of June 30, China’s innovative drugs have been out-licensed to foreign companies in 81 deals. • […]
Health
China innovative drug out-licensing deal value reaches new high in first half of 2026, says CCTV
Audio By Carbonatix
SHANGHAI, July 13 (Reuters) – The value of China’s innovative drug out-licensing deals reached about $110 billion between January and June, a record high, state broadcaster CCTV reported Monday, citing data from the National Medical Products Administration.
• As of June 30, China’s innovative drugs have been out-licensed to foreign companies in 81 deals.
• A licensing agreement grants a company the rights to develop, manufacture or commercialise another company’s pharmaceutical products or technologies in exchange for an upfront fee or future target-based payments, mitigating development risks.
• The deal value has already reached 80% of 2025’s full-year total.
• The products licensed covered therapeutic areas including oncology, metabolism, immunology, and neurology.
• The main licensee companies came from countries including the U.S., Britain, France and Italy.
• Global drugmakers are stepping up their search for China-developed experimental medicines ahead of patent expirations.
(Reporting by Andrew Silver in Shanghai; Editing by Jamie Freed)